Long‐term safety of adalimumab in adult patients with plaque psoriasis
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Dermatology"
DOI: 10.1111/bjd.17366
Abstract: Adalimumab is a powerful drug used to treat psoriasis, that has been specially designed to mimic normal human molecules, and for this reason it is classed as a ‘biological’ drug. It reduces inflammation by inhibiting… read more here.
Keywords: long term; safety; per 100; aes per ... See more keywords
THU0301 Safety following initiation of rituximab in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA): interim analysis of the rituximab in anca-associated vasculitis registry (RAVER)
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1177
Abstract: Background Therapy-related serious adverse events (SAEs) are important causes of morbidity in patients with GPA or MPA. Long-term safety data of rituximab in GPA/MPA are limited. Objectives To characterize safety events in an observational registry… read more here.
Keywords: rituximab; none declared; gpa mpa; safety ... See more keywords
Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy: Results From a Nationwide Danish Cohort Study
Sign Up to like & getrecommendations! Published in 2019 at "Circulation"
DOI: 10.1161/circulationaha.118.036248
Abstract: Background: Patients with atrial fibrillation generally require anticoagulant therapy and, at times, therapy with additional platelet aggregation inhibitors. Data are scarce on bleeding rates in high-risk groups receiving combination therapy, such as the elderly or… read more here.
Keywords: therapy; 100 pys; major bleeding; atrial fibrillation ... See more keywords